# BMS-986365

Source: https://onco.cc/drugs/bms-986365/  
OnCo record `bms-986365` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BMS-986365 is an experimental protein degrader from Celgene in phase 3 trials for prostate cancer, aimed at Androgen receptor.

## Summary

BMS-986365 is a protein degrader developed by Celgene. Its target is Androgen receptor (the sponsor names androgen receptor (AR)). The sponsor states: A dual androgen receptor ligand-directed degrader and antagonist, i.e. it both degrades the AR protein and blocks its activity. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06764485 (A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer), in prostate cancer. The largest, NCT06764485, plans to enrol 960 participants with primary completion expected 2027-09-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: protein degrader
- Mechanism: A dual androgen receptor ligand-directed degrader and antagonist, i.e. it both degrades the AR protein and blocks its activity.

## Sources

- ClinicalTrials.gov: trials of BMS-986365: https://clinicaltrials.gov/search?intr=BMS-986365

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- targets: [Androgen receptor](https://onco.cc/targets/androgen-receptor/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)
- trials: [A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer](https://onco.cc/trials/nct06764485/)

---
JSON: https://onco.cc/api/v1/entities/bms-986365.json